Royal Bank of Canada
ADAP

Royal Bank of Canada’s Adaptimmune Therapeutics ADAP Stock Holding History

Royal Bank of Canada’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-700
Closed -$1K – 6976
2024
Q1 		$1K Buy
700
+108
+18% +$130 ﹤0.01% 6745
2023
Q4 		$0 Sell
592
-18,433
-97% -$10.4K ﹤0.01% 7053
2023
Q3 		$15K Buy
19,025
+18,866
+11,865% +$15.8K ﹤0.01% 6271
2023
Q2 		$0 Buy
159
+130
+448% +$155 ﹤0.01% 7196
2023
Q1 		$0 Hold
29
– – ﹤0.01% 7015
2022
Q4 		$0 Sell
29
-58
-67% -$94 ﹤0.01% 7167
2022
Q3 		$0 Hold
87
– – ﹤0.01% 7394
2022
Q2 		$0 Hold
87
– – ﹤0.01% 7317
2022
Q1 		$0 Buy
87
+3
+4% +$8 ﹤0.01% 7697
2021
Q4 		$0 Buy
+84
New +$382 ﹤0.01% 7613
2021
Q2 		– Sell
-3,000
Closed -$16K – 7431
2021
Q1 		$16K Hold
3,000
– – ﹤0.01% 6551
2020
Q4 		$16K Buy
+3,000
New +$16.3K ﹤0.01% 6154
2020
Q3 		– Sell
-1,000
Closed -$10K – 6566
2020
Q2 		$10K Sell
1,000
-946
-49% -$5.94K ﹤0.01% 5819
2020
Q1 		$6K Sell
1,946
-1,108
-36% -$3.68K ﹤0.01% 5964
2019
Q4 		$3K Buy
3,054
+1,054
+53% +$1.12K ﹤0.01% 6466
2019
Q3 		$3K Hold
2,000
– – ﹤0.01% 6172
2019
Q2 		$8K Sell
2,000
-196
-9% -$799 ﹤0.01% 6088
2019
Q1 		$10K Buy
2,196
+196
+10% +$913 ﹤0.01% 5968
2018
Q4 		$12K Buy
2,000
+1,000
+100% +$7.38K ﹤0.01% 5786
2018
Q3 		$14K Hold
1,000
– – ﹤0.01% 5843
2018
Q2 		$12K Sell
1,000
-16
-2% -$200 ﹤0.01% 5757
2018
Q1 		$11K Buy
1,016
+951
+1,463% +$8.32K ﹤0.01% 5662
2017
Q4 		$0 Buy
+65
New +$502 ﹤0.01% 6492

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Royal Bank of Canada's ADAP Position: Q2 2024 in Review

Royal Bank of Canada sold out of Adaptimmune Therapeutics (ADAP) in Q2 2024, closing a stake of 700 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in ADAP in Q4 2017 and held it in 23 quarters. The position peaked at $16K in Q1 2021. 76 funds tracked by Wall St. Rank hold ADAP as of Q2 2024.

  • Royal Bank of Canada reported no remaining Adaptimmune Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 700 Adaptimmune Therapeutics shares in Q2 2024, an estimated $1K.
  • Royal Bank of Canada first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 23 quarters.
  • Royal Bank of Canada's Adaptimmune Therapeutics position peaked at $16K in Q1 2021.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2024.

Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.